Lyme Disease Treatment Market

Lyme Disease Treatment Market
Opportunity And Analysis 2026
-
Trends,
Lyme disease is an infectious disease, caused due to the bacterium – Borrelia burgdorferi,
which is transmitted to humans through bites of infected adult black-legged ticks. Most human
infections are caused by bites of nymphs (immature tick). Ticks can attach to any part of the
human body and can transmit the infection, if attached to the host body for 36 to 48 hours.
Blacklegged ticks are responsible for spreading Lyme disease in the northeastern, mid-Atlantic,
and north-central areas of the U.S. However, western black-legged ticks spread Lyme disease in
the regions along the Pacific Coast. These regions are thus, expected to witness rapid growth of
the market for Lyme disease treatment in the near future.
Request PDF Brochure Of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/862
The early symptoms associated with Lyme disease include fever, headaches, chills, fatigue,
muscle and joint aches, swollen lymph nodes, and characteristic skin rash (erythema migrans).
According to the Centers for Disease Control and Prevention (CDC), erythema migrans affects
around 70% to 80% of infected people, worldwide. However, untreated Lyme disease can lead
to further discomfort, which includes intermittent pain in muscles, tendons, joints, and bones,
coupled with severe headaches, neck stiffness, arthritis with severe joint pain, swelling in knees,
facial palsy, increased heart palpitations or an irregular heartbeat, nerve pain, and inflammation
of the brain and spinal cord.
Lyme carditis is a rare complication in Lyme disease, which occurs when infection invades the
tissue of the heart. This can interfere with normal heart rhythm resulting in mild, moderate, or
severe heart blockage. Patients may experience palpitations, lightheadedness, blackouts, chest
pain, and dyspnea. According to the National Surveillance Data, done by National Notifiable
Disease Surveillance System (NNDSS), between 2001 and 2010, Lyme carditis affected around
1% of patients suffering from Lyme disease, in the U.S. Lyme carditis can be treated with
intravenous or oral antibiotics, preferably ceftriaxone. However, some patients might require
implantation of a temporary or permanent pacemaker, depending upon the severity of infection.
Report includes chapters which deeply display the following deliverable about industry :
• Lyme Disease Treatment Market Research Objective and Assumption
• Lyme Disease Treatment Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Lyme Disease Treatment Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Lyme Disease Treatment Market, By Regions
• Lyme Disease Treatment Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Lyme Disease Treatment Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Lyme Disease Treatment Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Lyme Disease Treatment Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Antibiotics are found to be the most effective treatment for Lyme disease. Patients with early
stages of Lyme disease recover rapidly and completely with appropriate antibiotics such as
doxycycline, amoxicillin, and cefuroxime axetil. Patients with certain neurological or cardiac
illness may be treated with intravenous ceftriaxone. Patients bearing chronic symptoms of Lyme
disease for over 6 months, can recover within a few weeks, through oral antibiotic treatment.
According to International Lyme and Associated Disease Society (ILADS), Lyme disease is often
difficult to diagnose and treat, resulting in persistent infections.
ILADS recommends
individualized treatment based on the severity of symptoms, tick-borne coinfections, and
patient’s response to treatment. However, no single antibiotic or combination of antibiotics
appears to be capable of eliminating the Lyme disease infection. Therefore, the prevailing cases
of Lyme disease and large scope to develop the ideal antibiotic for treatment, are expected to
boost the Lyme disease treatment market in the near future.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/lyme-disease-treatment-market-862
Lyme Disease Treatment Market Taxonomy:
By disease type:
• Early Lyme disease (absence of erythema migrans)
• Lyme carditis
• Lyme arthritis
• neurologic Lyme disease
• Borrelial lymphocytosis
• Post-treatment Lyme Disease Syndrome (PTLDS)
By treatment:
• Doxycycline
• Amoxicillin
• Cefuroxime axetil
• Ceftriaxone
• Others (azithromycin, clarithromycin, erythromycin)
Increasing incidence to drive the Lyme disease treatment market in North America
Globally, North America accounts for largest share of the market, owing to the highest number
of Lyme disease cases reported here. According to Centers for Disease Control and Prevention
(CDC), around 28,453 confirmed cases of Lyme disease and 9 new cases per 1,00,000 people
were recorded in the U.S. during the 2005 - 2015. The European market is also expected to
experience rapid growth in the Lyme disease treatment market in near future. According to the
2014 factsheet of European Centre for Disease Prevention and Control (ECDC), prevalence of
Lyme disease is steadily increasing.
The major players operating in the Lyme disease treatment market include Lupin Ltd, Mylan
N.V., Sun Pharmaceuticals Industries Ltd., Pfizer Inc., G&W Laboratories, Inc., Teva
Pharmaceutical Industries Ltd., Sandoz AG, GlaxoSmithKline plc., and Hospira Inc.
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/
buy-now/862
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Lyme disease is an infectious disease, caused due to the bacterium – Borrelia burgdorferi, which is transmitted to humans through bites of infected adult black-legged ticks.

Download Report